Apr 28, 2020
Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs
Mar 24, 2020
Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development
Feb 25, 2020
Relmada Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference
Feb 13, 2020
VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview
Feb 11, 2020
VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects
Nov 07, 2019
VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview
Oct 21, 2019
i2020 Accelerator Invests in Developing Novel Highly-Specific Approaches to Treatment of Neurodegenerative Diseases Based on Previously Unrecognized Protein-Protein Interactions
Oct 14, 2019
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
Oct 08, 2019
VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder
Aug 16, 2019
IV Ketamine Infusions Dramatically Improve the Quality of Life for Severe Migraine Patient
Aug 05, 2019
Neurotrope Announces Corporate Update and Reports Second Quarter 2019 Financial Results
Jul 29, 2019
Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression
May 31, 2019
Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting
Apr 16, 2019
Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results
Apr 03, 2019
Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations
Mar 05, 2019
Houston based depression psychiatrist, Dr. Sandhya Prashad, M.D., tells how this new drug might save lives and cost less than expected
Feb 14, 2019
Amorsa Therapeutics Announces Notice of Allowance for U.S. Patent Covering Deuterated Norketamine and Related Compounds
Jan 03, 2019
New Data Published in the International Journal of Neuropsychopharmacology Support that Rapastinel May Produce Rapid and Sustained Antidepressant Effects Through a Potentially Novel Mechanism of Action
Oct 02, 2018
Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels
Aug 09, 2018
Relmada Therapeutics Allowed Patent Application in China Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms